Zdrowie i gospodarka · 29/11/2024
Use of Circulating Tumor Deoxyribonucleic Acid for Curative-Intent Solid Tumor Drug Development; Guidance for Industry; Availability
The US Food and Drug Administration (FDA) has released a final guidance for industry on using circulating tumor DNA for curative-intent solid tumor drug development, providing clarity for sponsors planning to use this biomarker in cancer clinical trials.